Last updated: July 28, 2026
chnetium Tc-99m Tilmanocept (Lymphoseek) Clinical Trials Update, Market Analysis, and Projection
Technetium Tc-99m tilmanocept (Lymphoseek) is an FDA-approved radiopharmaceutical used for mapping sentinel lymph nodes in breast cancer, melanoma, and squamous cell carcinoma of the skin. Public clinical development since approval has been limited, with the near-term competitive and growth outlook driven more by label expansion, imaging practice adoption, and reimbursement dynamics than by large late-stage trials.
What is Technetium Tc-99m tilmanocept and what indication does it cover in the US?
Featured snippet: Lymphoseek is approved for intraoperative detection/mapping of sentinel lymph nodes in patients with: breast cancer, melanoma, and squamous cell carcinoma of the skin. It is administered as a radiolabeled tilmanocept (Tc-99m) and used with a gamma detection system.
How does Lymphoseek work vs. blue dye and colloids?
Tilmanocept is a mannosylated scaffold designed to bind CD206 (mannose receptor) on macrophages/antigen-presenting cells, which can support lymphatic trafficking and retention in sentinel lymph nodes. In practice, it is used alongside or as an alternative to blue dye, depending on institutional workflow and preference.
Route, timing, and typical clinical workflow
Lymphoseek is injected per label for sentinel lymph node mapping; surgery is then performed after tracer uptake, using a gamma probe to identify sentinel nodes and support intraoperative decisions. (Dosing, timing windows, and procedural constraints depend on the specific labeled population and setting.)
What clinical trials exist for Technetium Tc-99m tilmanocept after FDA approval?
Featured snippet: Post-approval public trial activity is comparatively sparse in the late-stage registries compared with many oncology therapeutics. Current visibility is dominated by: (1) label-supportive studies already completed around approval, and (2) smaller procedural, imaging performance, or workflow studies.
Which trial types remain most common post-approval?
Across radiopharmaceuticals, the main recurring study types after first approval include:
- Head-to-head or comparative mapping performance studies (detection rates, false-negative rates, time-to-identification)
- Multicenter “real-world” or operational studies (workflow integration, gamma probe performance, dose handling)
- Technical and procedural studies (injection-to-surgery interval, site-specific mapping optimization)
What do recent public updates indicate about endpoints?
Where post-approval data appear, they generally focus on:
- Sentinel lymph node identification rate
- Sentinel node yield per patient
- Conversion from non-sentinel to sentinel identification (if applicable)
- False-negative rate measures
- Safety endpoints centered on radiotracer administration
(Clinical-trial visibility for tilmanocept is lower than for many systemic agents, so market outcomes typically track adoption more than late-stage pipeline breakthroughs.)
How strong is the patent estate for Technetium Tc-99m tilmanocept (Lymphoseek) and what risks exist for competition?
Featured snippet: The competitive landscape is constrained by IP and regulatory barriers typical for radiopharmaceuticals, including process know-how, formulation control, radionuclide preparation parameters, and exclusivity or Orange Book–linked protection where applicable.
Where do generic or “copy” risks usually materialize for radiopharmaceuticals?
Even where a drug’s core concept is a known radionuclide conjugate, competitors often need to match:
- Specific scaffold chemistry and radiolabeling parameters
- Manufacturing controls that affect in vivo distribution and imaging performance
- Evidence for comparable performance in labeled mapping settings
- Regulatory pathways that can require substantial clinical or bridging evidence
What drives the practical barrier: IP or CMC?
For radiopharmaceuticals, CMC and reproducibility typically matter as much as the core patent coverage because small changes can impact lymphatic kinetics and imaging signal quality.
What is the Orange Book status of Technetium Tc-99m tilmanocept?
Featured snippet: Lymphoseek’s exclusivity and patent listing status is determined by FDA’s Orange Book listings for the specific NDA product and strengths.
How does Orange Book coverage typically affect market entry timing?
Entry risk depends on:
- Patent expiry dates for composition and manufacturing/process claims
- Exclusivity periods that can delay approval of competing applications
- Whether listed patents are tied to the clinically relevant performance characteristics or merely to ancillary claims
What is the market for sentinel lymph node mapping tracers in breast cancer, melanoma, and SCC of the skin?
Featured snippet: The total addressable market (TAM) is driven by the number of eligible patients undergoing sentinel lymph node biopsy and the proportion who receive radiotracer-based mapping, either as standard-of-care or in combination with blue dye.
Key demand drivers
- Volume of breast lumpectomy and mastectomy cases where sentinel node mapping is used
- Melanoma excision volume, especially intermediate thickness disease where SLNB is common
- SCC of the skin use where sentinel mapping is adopted in surgical oncology workflows
- Uptake of gamma-probe imaging versus alternatives, influenced by tracer performance and operational fit
Key cost and reimbursement drivers
- Hospital or ASC reimbursement patterns for SLNB and imaging
- Nuclear medicine department capacity to prepare and supply Tc-99m agents
- Contracting and pharmacy logistics, including radionuclide supply chain reliability
How does Technetium Tc-99m tilmanocept compare with other sentinel lymph node mapping tracers?
Featured snippet: Lymphoseek is positioned as a targeted radiotracer with consistent sentinel lymph node uptake intended to improve mapping performance relative to non-targeted colloids and/or to simplify intraoperative identification workflows.
Competitor categories
- Nonspecific Tc-99m colloids used in sentinel node mapping
- Other radiopharmaceuticals used by institutional protocol
- Blue dye-based strategies (often combined with radiotracers)
What matters in real-world adoption
Market share is typically influenced by:
- Sentinel lymph node identification rates and false-negative performance
- Workflow: injection-to-probe identification timing and ease of localization
- Supply reliability from radiopharm networks
- Clinician familiarity and procurement contracts
What clinical endpoints matter most for payer and hospital adoption?
Featured snippet: Hospitals adopt sentinel node tracers when the tracer supports high sentinel node identification and reduces the chance of missed sentinel nodes, reducing downstream re-operations, additional node sampling, and staging uncertainty.
Primary performance signals
- Identification rate (per patient, per hemithorax/side where relevant)
- Number of sentinel nodes retrieved
- False-negative rate proxies and comparable performance to standard-of-care
- Safety and tolerability of the radiotracer administration
What is the clinical trials outlook: are there late-stage expansion programs likely to change label or utilization?
Featured snippet: Near-term utilization is most sensitive to practice adoption and any incremental evidence supporting expanded use, rather than to major new late-stage clinical readouts that would rapidly reframe adoption.
What would materially move the market projection
- Label expansion into additional histologies or procedure contexts
- New procedural standards that favor targeted tracers over alternatives
- Evidence that improves detection performance in subgroups where mapping is challenging
- Cost and contracting improvements that increase net reimbursement attractiveness
What is the market outlook and revenue projection for Technetium Tc-99m tilmanocept?
Featured snippet: A credible revenue forecast for Lymphoseek depends on (1) SLNB procedure volumes, (2) tracer penetration rate versus alternative tracers, and (3) average annual doses per treated patient in labeled indications. Without access to proprietary unit data, projections should be anchored to publicly observable adoption proxies like nuclear medicine purchasing trends, institutional uptake, and radiopharmacy distribution scale.
Projection framework (how analysts typically model uptake)
A high-level model uses:
- Eligible patient volume by indication (breast, melanoma, SCC skin)
- SLNB utilization rate within those indications
- Radiotracer usage share and share of targeted tracer within radiotracers
- Doses per procedure by labeled mapping protocol
- Average net price (after rebates/discounts and contract mix)
- Supply and competitive entry effects
Most likely scenario drivers for 2026 to 2030
- Growth tied to overall surgical oncology procedure volumes
- Gradual share gains if Lymphoseek demonstrates robust performance in routine workflows
- Ceiling effects if institutions already standardize on alternative tracers or have procurement lock-in
- Competitive impact if biosimilar-style competitive dynamics do not apply, then generics/copies remain constrained, supporting pricing durability
What generic entry risks exist for Technetium Tc-99m tilmanocept?
Featured snippet: Entry risk is structurally lower than in typical chemical drugs because radiolabeling reproducibility, CMC complexity, and performance/bridging evidence requirements create substantial barriers for true “copy” competitors.
Where do risks concentrate
- Any approach that can demonstrate comparable lymph node uptake and imaging performance under labeled conditions
- CMC and manufacturing improvements that reduce variability and enable consistent product characteristics
- Patent carve-outs, settlements, or non-infringing process alternatives
What patent litigation affects Technetium Tc-99m tilmanocept and competitors?
Featured snippet: Litigation for radiopharmaceuticals can involve product/process patents, method claims tied to imaging performance, or disputes over Orange Book listed claims. Public docket visibility determines the competitive timing impact.
Settlement patterns that typically influence market timing
- License agreements with defined entry dates
- Carve-outs limiting competition to non-overlapping claims or indications
- Staged entry aligned with exclusivity expiry
Which companies are challenging the Technetium Tc-99m tilmanocept franchise?
Featured snippet: Competing threats most often come from radiopharmaceutical manufacturers with:
- Tc-99m radiolabeling capabilities
- Ability to scale production and meet hospital supply requirements
- Regulatory strategies that can bridge performance evidence
How to assess competitor readiness
- Manufacturing network footprint for Tc-99m agent distribution
- Prior experience with SLN tracer development or commercialization
- Track record with FDA CMC expectations for radiolabeled constructs
How does regulatory status in the US shape market access and forecasting?
Featured snippet: US label status determines reimbursement inclusion in many hospital protocols and directly sets the eligible physician-patient population for tracer procurement.
FDA pathway implications
For radiopharmaceuticals, regulatory pathways can require:
- Product-specific evidence of safety and performance
- Demonstration of comparable radiochemical purity and stability
- Bridging studies depending on application type and reference product reliance
Key Takeaways
- Technetium Tc-99m tilmanocept (Lymphoseek) has an established US sentinel lymph node mapping role in breast cancer, melanoma, and SCC of the skin; post-approval clinical development is visible mainly through smaller or operational studies rather than frequent late-stage readouts.
- Market growth is likely driven more by sentinel lymph node biopsy volumes and tracer penetration than by dramatic pipeline turns.
- Competitive entry is structurally constrained for radiopharmaceuticals by CMC, radiolabel reproducibility, and the need to match labeled imaging performance, which can support pricing and reduce generic-like timing pressure relative to systemics.
- Revenue projections should be modeled off procedure volumes, SLNB utilization, tracer penetration, dosing frequency, and net pricing, adjusted for contract mix and supply dynamics.
FAQs
- What is the sentinel lymph node identification rate for Technetium Tc-99m tilmanocept in breast cancer vs melanoma?
- How do hospitals decide between Lymphoseek and alternative Tc-99m colloids for sentinel node mapping?
- What are the main reimbursement and contracting factors that drive net price for Lymphoseek?
- What CMC and radiolabeling controls are critical for producing Tc-99m tilmanocept competitively?
- If a new competitor enters with a comparable Tc-99m targeted tracer, what adoption barriers slow uptake?
References (APA)
- FDA. (n.d.). Lymphoseek (technetium Tc 99m tilmanocept) prescribing information. U.S. Food and Drug Administration.
- FDA. (n.d.). Drugs@FDA: Lymphoseek (technetium Tc 99m tilmanocept). U.S. Food and Drug Administration.
- FDA. (n.d.). Orange Book: Lymphoseek. U.S. Food and Drug Administration.
- ClinicalTrials.gov. (n.d.). Technetium Tc-99m tilmanocept studies. U.S. National Library of Medicine.
